| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
The purpose of this study is the development of a new treatment for oral cancer indicating the resistance for the anticancer effect of cetuximab by using hyperthermia generated with contrast agent Resovist in an alternating magnetic field(AMF) and Cetuximab.We found that the expression of EGFR in human oral squamous cell carcinoma cells increased by thermal stimulation.Therefore, we thought that the sensitivity of Cetuximab-resistant human oral squamous cell carcinoma cells for cetuximab can be activated by thermal stimulation-induced high expression of EGFR.As a result of the study using mouse models based on this speculation, the anti-cancer effect were observed in the group treated with combination of cetuximab and hyperthermia generated with contrast agent Resovist in AMF.
|
